TASLY(SH:600535)2023-04-24 16:00Financial Performance - The company's revenue for Q1 2023 was ¥2,080,286,985.33, representing a 10.92% increase compared to ¥1,869,322,335.61 in the same period last year[4] - Net profit attributable to shareholders was ¥266,078,260.25, a significant turnaround from a loss of ¥557,187,364.10 in the previous year, marking a 147.71% increase[4] - Basic and diluted earnings per share were both ¥0.1774, compared to a loss of ¥0.3719 per share in the previous year, reflecting a 147.71% improvement[6] - Operating profit for Q1 2023 was ¥387,974,445.95, a significant recovery from a loss of ¥560,772,114.19 in Q1 2022[19] - Net profit for Q1 2023 was ¥262,651,994.66, compared to a net loss of ¥595,754,133.68 in the same period last year[20] - The company reported a significant decrease in other comprehensive income, with a net loss of ¥114,242,766.88 in Q1 2023 compared to a loss of ¥910,065.68 in Q1 2022[20] - The company's total equity increased to ¥12,820,339,753.74 in Q1 2023, compared to ¥12,680,543,185.34 in Q1 2022[19] Cash Flow - The net cash flow from operating activities increased by 78.91% to ¥149,327,174.29, up from ¥82,228,958.20 in the same period last year[4] - Cash inflow from operating activities totaled CNY 2,362,200,210.33, an increase of 13.5% compared to CNY 2,080,743,156.20 in the previous year[22] - Cash outflow from operating activities was CNY 2,212,873,036.04, up from CNY 1,997,278,300.36, resulting in a net cash flow from operating activities of CNY 149,327,174.29, compared to CNY 83,464,855.84 last year[22] - The net cash flow from operating activities was -483,016,944.40, a significant decrease compared to 199,955,253.89 in the previous year[30] - Cash inflow from financing activities amounted to CNY 1,521,358,992.29, compared to CNY 872,708,017.39 in the previous year, indicating a significant increase[23] - The net cash flow from financing activities was 1,534,145,347.22, compared to 247,702,958.29 in the same period last year[30] Assets and Liabilities - Total assets at the end of the reporting period were ¥17,767,651,578.68, an increase of 8.05% from ¥16,430,265,605.64 at the end of the previous year[6] - The company's total liabilities increased to ¥4,947,311,824.94 in Q1 2023, compared to ¥3,763,901,169.64 in Q1 2022, indicating increased leverage[19] - The company's total current assets rose to CNY 7,148,547,322.25, compared to CNY 6,349,554,013.25 in the previous year, marking an increase of 12.6%[24] - The company's total liabilities increased to CNY 4,581,434,879.23 from CNY 3,020,530,113.87, indicating a rise of 51.7%[25] - The total assets of the company reached approximately RMB 17.77 billion, an increase from RMB 16.44 billion in the previous year, reflecting a growth of about 8.06%[16] Investments - The company invested RMB 300 million in guaranteed convertible bonds and RMB 395 million in equity of Yongtai Biological, indicating a strategic investment in the biopharmaceutical sector[13] - The company holds a 39% stake in the Shaoxing Tianshili Biopharmaceutical Industry Equity Investment Fund, with an investment of RMB 390 million[14] - Long-term equity investments increased to CNY 6,147,710,928.77 from CNY 5,251,425,896.89, representing a growth of 17.1%[25] - The company reported a financial asset fair value loss of CNY -14,068,538.24 in Q1 2023, compared to a loss of CNY -110,869,184.43 in Q1 2022[29] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 57,109[11] - The largest shareholder, Tianjin Tianshili Holding Group Co., Ltd., holds 45.57% of the shares, totaling 683,481,524 shares[11] Research and Development - Research and development expenses increased to ¥165,502,150.85 in Q1 2023, up from ¥137,167,743.59 in Q1 2022, reflecting a focus on innovation[19] - Research and development expenses rose to CNY 93,249,352.35, up 40.83% from CNY 66,213,264.07 in Q1 2022[27] Inventory and Receivables - The company's accounts receivable decreased to RMB 764.99 million from RMB 891.93 million, representing a decline of about 14.2%[15] - The inventory increased to RMB 1.65 billion, compared to RMB 1.52 billion, showing a growth of approximately 8.9%[16] Cost Management - The cost of goods sold decreased to CNY 465,754,348.12, down 6.81% from CNY 499,715,039.52 in the same period last year[27] - The company's financial expenses decreased to ¥11,919,014.36 in Q1 2023 from ¥14,588,821.80 in Q1 2022, reflecting improved cost management[19]